In contrast to the non-degrader form of ACBI1, which had no anti-cancer effect, the ACBI1 PROTAC killed SMARCA4-dependent leukemia cells as well as SWI/SNF-deficient cancer cells that are dependent on residual SWI/SNF activity. Here, SMARCA1 is linked to cancer.